Diazepam intranasal spray

Drug Profile

Diazepam intranasal spray

Alternative Names: DZNS; Plumiaz; SK-DZNS

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK Holdings
  • Developer Acorda Therapeutics
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 10 Jun 2016 Acorda Therapeutics completes a pharmacokinetics phase I trial in Healthy volunteers in USA (Intranasal, Spray) (NCT02663999)
  • 24 May 2016 Discontinued - Preregistration for Epilepsy in USA (Intranasal)
  • 29 Feb 2016 Acorda Therapeutics announces intention to submit NDA to the US FDA in 2017 (Acorda Therapeutics, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top